Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the chinese population
- 1 February 2000
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 66 (14) , PL175-PL181
- https://doi.org/10.1016/s0024-3205(00)00446-x
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Genetic polymorphism of (S)‐mephenytoin 4′‐hydroxylation in populations of African descentBritish Journal of Clinical Pharmacology, 1999
- genotype status and effect of omeprazole on intragastric pH in humansClinical Pharmacology & Therapeutics, 1999
- Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic UlcerAnnals of Internal Medicine, 1998
- Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysisPharmacogenetics, 1996
- Geographical/Interracial Differences in Polymorphic Drug OxidationClinical Pharmacokinetics, 1995
- Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trialClinical Pharmacology & Therapeutics, 1994
- Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokineticsClinical Pharmacology & Therapeutics, 1992
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland ChineseClinical Pharmacology & Therapeutics, 1989
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985